PPIDT00432
Drug Information
| Name | Faricimab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15303 |
| Type | biotech |
| Indication | Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).[L40026] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravitreal |
120 mg/ml
|
| Injection, solution | Intravitreal |
6 mg/0.05mL
|
| Solution | Intraocular |
6 mg
|
| Solution | Intraocular |
6.00 mg
|
| Solution | Intraocular |
600000 mg
|
| Solution | Intravitreal |
6 mg / 0.05 mL
|
| Solution | Intravitreal |
6 mg/0.05mL
|